“TaiMed Biologics is at the forefront of innovation in HIV therapy and offers contract development and manufacturing organization (CDMO) services, reshaping the treatment paradigm for patients worldwide,” shared CEO Jimmy Chang.
Founded in Taiwan in 2007, TaiMed Biologics pioneers innovation in biopharmaceuticals, aiming to transcend traditional boundaries and redefine HIV treatment through groundbreaking therapies.
“Trogarzo is the first in its class, approved for HIV therapy, for multi-drug-resistant conditions,” Chang emphasized. “Launched successfully in the U.S. in 2018, the drug marked a significant milestone in HIV treatment, with the marketing rights of Trogarzo available for regions outside the U.S., including Japan. Building on Trogarzo’s success, TaiMed is dedicated to innovating HIV treatment,” Chang said. The company began by licensing and developing the antibody from Genentech, which achieved several world records with its revolutionary drug.
TaiMed is currently advancing a second-generation HIV therapy, aiming to introduce the first long-acting antibody for the virus. The therapy targets a bimonthly injection schedule to alleviate patient stress associated with daily pill consumption and to address issues such as viral mutation.
“We envision a future where HIV treatment is more accessible, effective, and patient-centric,” Chang said. TaiMed is currently seeking partnerships for further development.
In addition to HIV innovation, TaiMed is offering CDMO services for biologics, ensuring top-notch quality from development to market.
TaiMed Biologics is at the forefront of innovation in HIV therapy and offers contract development and manufacturing organization (CDMO) services, reshaping the treatment paradigm for patients worldwide.
Jimmy Chang, Chief Executive Officer of TaiMed
“With a cutting-edge manufacturing facility adhering to good manufacturing practices in Taiwan, TaiMed provides end-to- end support, driven by expertise in monoclonal antibody products,” he explained.
Through strategic partnerships and collaborations, TaiMed aims to expand its reach and impact in the global market, particularly in Japan. “We are committed to driving biopharmaceutical innovation forward,” Chang said.
TaiMed Biologics’ commitment to excellence extends beyond mere innovation; it embodies a steadfast dedication to improving the lives of HIV patients globally. As Chang highlighted, controlling HIV is vital for patients’ well-being and in preventing the spread of the virus. With a mission to fulfill unmet medical needs, TaiMed Biologics continues to blaze new trails in the fight against HIV, promising a brighter future for patients worldwide.
